Cite

HARVARD Citation

    Awada, A. et al. (n.d.). 1172PA first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors. Annals of oncology. p. . [Online]. 
  
Back to record